ERBB2 and breast carcinoma: In addition to trastuzumab, other targeted therapies, including macromolecular monoclonal antibodies, small-molecule TKIs, and cytotoxic drugs, have gradually clarified their benefits and therapeutic status in HER2-positive breast cancer brain metastases, respectively [40, 46, 84].